Dendritic therapy

The human body creates malignant cells everyday. The immune system battles with them in such a way that it creates an antigen that prevents their proliferation, or feeding with material from the bloodstream. So they die and the body expels them from the body in various ways. The transporter of these antigens is antibodies. They circulate and transmit the antigen. When antibodies miss any of the malignant cells, an oncological disease occurs, or the malignant cells begin to multiply. In order to improve the system of fighting in the body, laboratory-produced antibodies called dendritic cells are introduced. Antigen is produced in the laboratory, placed on laboratory-produced antibodies and returned to the body. Antibodies are additionally stimulated to propagate massively in the body.

Apoptosis inducer SOT Therapy

SOT Therapy has been shown to be a very supportive treatment for cancer. SOT Therapy has the ability to induce apoptosis (cell death) in CTCs, CSCs and primary tumor cell. From a blood sample the CTCs are identified, than a small molecule call microRNA is developed to match exactly into a “lock” portion of the cancer cell that controls vital cell functions.
The SOT Therapy is injected intravenously, spreads through the body including past the blood-brain barrier, embeds into the cancer and will disrupt the ability of the cancer or pathogen to replicate.
SOT Therapy has a stealth like ability to avoid destruction and will work 24/7 to fight cancer for as long as 6 months.

Vaccine Prep from Fragmented Tumor Cells

Traditional cancer vaccines target different types of self-antigens, including overexpressed tumor-specific proteins and oncogenes that might also represent universal antigens among patients with the same malignancy.
R.G.C.C. developed a tumor vaccine consisting of fixed carcinoma cells. The vaccine containing human autologous carcinoma fragments. Such a vaccine aiming to enhance T-Cell responses.